BioSyent Inc. (TSXV:RX)

Market Cap	177.89M +31.6%
Revenue (ttm)	55.67M +40.9%
Net Income	9.87M +19.5%
EPS	0.85 +20.4%
Shares Out	11.31M
PE Ratio	18.42
Forward PE	15.20
Dividend	0.22 (1.40%)
Ex-Dividend Date	Aug 31, 2026

Volume	427
Open	16.18
Previous Close	16.06
Day's Range	15.73 - 16.18
52-Week Range	10.65 - 16.25
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 17, 2026

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2025, BioSyent's revenue was 43.05 million, an increase of 22.90% compared to the previous year's 35.03 million. Earnings were 9.01 million, an increase of 23.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error